🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04852406
Recruiting Not applicable

Protocol-based Management and Perioperative Outcomes in Patients With Chronic Antithrombotic Therapy

NCT04852406 · tracked via the Priya Life Science China tracker
Sponsor
Peking University First Hospital
Phase
Not applicable
Started
2021-04-21
Last updated
2025-07-31

Condition(s) studied

Antithrombotic TherapyPerioperative CarePerioperative Outcomes

Investigational drug(s) / intervention(s)

Protocol-based management of perioperative antithrombotic therapyRoutine management of perioperative antithrombotic therapy

Protocol-based management of perioperative antithrombotic therapy: Perioperative antithrombotic therapy is managed according to the latest expert consensus published in the Chinese Medical Journal, 2020.

Routine management of perioperative antithrombotic therapy: Perioperative antithrombotic therapy is managed according to current routine practice.

Study summary

The purpose of this pragmatic interventional study is to evaluate whether a protocol-based management of antithrombotic drugs can reduce a composite of perioperative outcomes in patients with chronic antithrombotic therapy before surgery.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: * 1\. Patients with continuing antithrombotic therapy (including antiplatelet and/or anticoagulant therapies) for cardiovascular and cerebrovascular diseases for more than 2 weeks. * 2\. Patients who have one or more of the following situations: (1) non-valvular atrial fibrillation with a CHA2DS2-VASc score \>4; (2) post-artificial valve replacement (including mitral valve, ball-cage valve or tilting disc aortic valve); (3) venous thromboembolism occurred within 1 year, or venous thromboembolism with other high-risk factors which require long-term anticoagulation treatment; (4) coronary heart disease with coronary stent implantation, thrombolytic therapy or other coronary procedures within 2 years, or who had undergone coronary artery bypass grafting within 1 year, or who experienced myocardial infarction or acute coronary syndrome within 1 year; (5) a history of stroke/transient ischemic accident within 1 year, or a history of cervical or intracranial revascularization treatment within 1 year; (6) peripheral arterial disease. * 3\. Patients who are scheduled to undergo intra-abdominal surgery (including general and urologic surgery). * 4\. Patients who sign written informed consents. Exclusion Criteria: * 1\. Refuse to participate. * 2\. Emergency surgery. * 3\. Unable to complete the preoperative assessment and follow-up plan. * 4\. Other reasons that are considered unsuitable for study participation by the investigators or the attending doctors.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking University First Hospital Beijing Beijing Municipality Recruiting

More Peking University First Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04852406 on ClinicalTrials.gov ↗ ← All trials in China